Sign Up to like & get
recommendations!
1
Published in 2022 at "Communications Biology"
DOI: 10.1038/s42003-022-03182-6
Abstract: Agonistic CD27 monoclonal antibodies (mAb) have demonstrated impressive anti-tumour efficacy in multiple preclinical models but modest clinical responses. This might reflect current reagents delivering suboptimal CD27 agonism. Here, using a novel panel of CD27 mAb…
read more here.
Keywords:
receptor clustering;
engineering;
agonistic cd27;
cd27 ... See more keywords